NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases.
According to Nayak, Axpaxli (axitinib intravitreal implant) is “a single injection, a single completely bioabsorbable hydrogel that provides continuous and consistent inhibition of all VEGF receptors for up to 12 months.”
Nayak said Axpaxli has shown positive data in three studies investigating the therapy as a treatment for wet age-related macular degeneration and diabetic retinopathy. It is currently